Alexandre Loiseau - MAUNA KEA CEO, Director

MKEA -- France Stock  

EUR 1.52  0.014  0.91%

  CEO
Mr. Alexandre Loiseau has served as a Chief Executive Officer and Director at Mauna Kea Technologies SA since May 2000. He started his career at the National Center for Space Studies in Toulouse and at the Paris Observatory then joined NASA Jet Propulsion Laboratory in Pasadena California as a research scientist. He is a graduate of Ecole Polytechnique and holds a Ph.D. in Astrophysics and Optical Instrumentation.
  CEO Since 2000  Ph.D    
33 1 48 24 03 45  http://www.maunakeatech.com

Management Efficiency

The company has return on total asset (ROA) of (31.57) % which means that it has lost $31.57 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (103.43) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 7.06M in total debt with debt to equity ratio (D/E) of 88.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. MAUNA KEA TECH has Current Ratio of 3.16 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 5 records

CEO Since

Marie MeynadierEOS IMAGING
2018
Mike LobinskyEOS IMAGING
2019
Bernard DoorenbosSUPERSONIC IMAGINE
2015
Michele LesieurSUPERSONIC IMAGINE
2016
Herve LegrandEOS IMAGING
N/A

Entity Summary

Mauna Kea Technologies SA, a medical device company, designs, develops, and markets endomicroscopy and optical biopsy tools for the diagnosis and treatment of gastrointestinal cancers and other diseases worldwide. The company was founded in 2000 and is headquartered in Paris, France. MAUNA KEA operates under Medical Devices classification in France and is traded on Paris Stock Exchange. It employs 100 people.MAUNA KEA TECH (MKEA) is traded on Paris Stock Exchange in France and employs 100 people.

MAUNA KEA TECH Leadership Team

Alexandre Loiseau, CEO, Director
Guillaume Bailliard, President for North America
Robert Gershon, CEO, Director
Francois Lacombe, Chief Scientific Officer
Christopher Tihansky, Chief Devel. Officer and President of North America
JeanLuc Boulnois, Director
Marion Ghibaudo, Director of Research & Development
Agnes Rouffiac, Director of Human Resources
Sebastien Cadet, Global Director of Marketing and OEM Leader
Sacha Loiseau, Founder, CEO and Director
Christophe Lamboeuf, Deputy Managing Director, CFO
Pierre Forest, COO
John Soto, COO
Olivier Regnard, Deputy CEO, CFO
Bertrand Talhouet, Representative of Creadev on the Board of Directors
Eric Cohen, CFO and VP of Fin.
Gilles Brisson, Chairman, Independent Director
Christopher McFadden, Director
Severine Cadiou, Director of Human Resources
Aline Criton, Regulatory and Clinical Affairs and Scientific Communication Director
Bruno Villaret, Vice President of International Sales
Joseph DeVivo, Non-Executive Independent Director
Christophe Bailleul, Vice-President Clinical Affairs, Health Economics and Market Access
Veronique Dentan, Director of Operations
Molly ONeill, Director
Jennifer Tseng, Independent Director
Marie Meynadier, Director

Stock Performance Indicators

Did you try this?

Run Risk-Return Analysis Now

   

Risk-Return Analysis

View associations between returns expected from investment and the risk you assume
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Search macroaxis.com